Neurofibromatosis Treatment Drugs Market
- 2026 年市場規模
- USD 20,785 Mn
- 2033 年預估規模
- USD 49,085 Mn
- 年複合成長率 CAGR
- 13.4%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Neurofibromatosis Treatment Drugs Market, By Disease Type (Neurofibromatosis 1 (NF1), Neurofibromatosis 2 (NF2), Schwannomatosis), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
報告摘要
Neurofibromatosis is a genetic disorder of the nervous system. It mainly affects growth of nerve cells. It is characterized by the growth of tumors on nerves. Neurofibromatosis is considered as a hereditary disease which mainly occurs in children or it can happen due to mutation (change) of genes. Usually the Neurofibromatosis tumors are benign, but sometimes they can become cancerous. There are three types of neurofibromatosis: Type 1 (NF1), Type 2 (NF2), and Schwannomatosis. All three types show varied symptoms.
Market Dynamics
The increasing focus of pharma and biotech companies on the research and development of novel treatment drugs for neurofibromatosis is expected to drive the neurofibromatosis treatment drugs market growth during the forecast period. For instance, on July 8, 2020, Nobelpharma initiated phase 3 clinical trial study to evaluate the safety and efficacy of long-term treatment with NPC-12G gel for patients with neurofibromatosis type I. The study is estimated to complete in April 30, 2022.
Key features of the study
• This report provides in-depth analysis of the global neurofibromatosis treatment drugs market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global neurofibromatosis treatment drugs market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key company covered as a part of this study includes AstraZeneca
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
• The global neurofibromatosis treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurofibromatosis treatment drugs market.
Neurofibromatosis Treatment Drugs Market Segmentation
• By Disease Type (Revenue, USD Mn, 2026-2033)
o Neurofibromatosis 1 (NF1)
o Neurofibromatosis 2 (NF2)
o Schwannomatosis
• By Distribution Channel (Revenue, USD Mn, 2026-2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• By Region (Revenue, USD Mn, 2026-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o AstraZeneca
o SpringWorks Therapeutics
o Novartis
o Pfizer
o Takeda Pharmaceutical
o Roche
o Healx
o NFlection Therapeutics
o Fosun Pharmaceutical
o Recursion Pharmaceuticals
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snippet, By Disease Type
Market Snippet, By Distribution Channel
Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Impact Analysis
o Market Opportunities
o Collaborations and Acquisition
o Regulatory Scenario
4. Global Neurofibromatosis Treatment Drugs Market, By Disease Type, 2021-2033 (USD Mn)
o Introduction
Market Share Analysis, 2026, and 2033 (%)
Y-o-Y Growth Analysis, 2022 - 2033
Segment Trends
o Neurofibromatosis 1 (NF1)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Neurofibromatosis 2 (NF2)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Schwannomatosis
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
5. Global Neurofibromatosis Treatment Drugs Market, By Distribution Channel, 2021-2033 (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Hospital Pharmacies
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Retail Pharmacies
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Online Pharmacies
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
6. Global Neurofibromatosis Treatment Drugs Market, By Region, 2021-2033 (USD Mn)
o Introduction
Market Share Analysis, By Region, 2026, and 2033 (%)
Y-o-Y Growth Analysis, For Region, 2022 - 2033
o North America
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Disease Type, 2026- 2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
o U.S.
o Canada
o Latin America
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Disease Type, 2026- 2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Disease Type, 2026- 2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
o Germany
o U.K.
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Disease Type, 2026- 2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Disease Type, 2026- 2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
o GCC
o Israel
o Rest of Middle East
o Africa
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Disease Type, 2026- 2033, (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Mn)
Market Size and Forecast, By Country, 2026- 2033, (USD Mn)
o South Africa
o Central Africa
o North Africa
7. Competitive Landscape
o Company Profiles
AstraZeneca Plc
o Company Overview
o Disease Type Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
SpringWorks Therapeutics
o Company Overview
o Disease Type Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Novartis
o Company Overview
o Disease Type Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Pfizer
o Company Overview
o Disease Type Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Takeda Pharmaceutical
o Company Overview
o Disease Type Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Roche
o Company Overview
o Disease Type Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Healx
o Company Overview
o Disease Type Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
NFlection Therapeutics
o Company Overview
o Disease Type Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Fosun Pharmaceutical
o Company Overview
o Disease Type Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Recursion Pharmaceuticals
o Company Overview
o Disease Type Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
8. Analyst Recommendations
o Wheel of Fortune
o Analyst View
o Coherent Opportunity Map
9. References and Research Methodology
o References
o Research Methodology
o About us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們